In The News
Preclinical data: Immunome’s cocktail holds Delta variant at bay
July 20, 2021 – By Lee Landenberger
New preclinical data from Immunome Inc. gets the company closer to the clinic for studying its three-antibody cocktail’s effect on SARS-CoV-2. “We will file an IND this quarter and get into the clinic,” Immunome’s CEO, Purnanand Sarma, told BioWorld. “Since the number of cases is rising, unfortunately, we think a clinical study could be conducted reasonably quickly.”
Anti-Infectives
COVID-19
DiMuzio et al, (2021) Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein, Vaccine (https://doi.org/10.1016/j.jvacx.2021.100098)
Casadevall et al, (2020) A randomized trial of convalescent plasma for COVID-19 – Potentially hopeful signals, JAMA (http://doi.org/doi:10.1001/jama.2020.10218)
Hachim et al, (2020) Beyond the Spike: identification of viral targets of the antibody response to SARS-CoV-2 in COVID-19 patients, (https://doi.org/10.1101/2020.04.30.20085670)
Li et al, (2020) Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial, JAMA (http://doi.org/doi:10.1001/jama.2020.10044)
Polio
Kouiavskaia et al. (2020) Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines, J Virol Methods 276:113785 (http://doi.org/doi: 10.1016/j.jviromet.2019.113785)
Puligedda et al, (2020) Human IgA Monoclonal Antibodies That Neutralize Poliovirus, Produced by Hybridomas and Recombinant Expression, Antibodies 9, 5 (http://doi.org/doi:10.3390/antib9010005)
Puligedda et al, (2017) Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes, Vaccine 35, 5455–5462 (http://doi.org/doi:10.1016/j.vaccine.2017.03.038)
Puligedda et al, (2014) Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains, Antiviral Res 108, 36–4 (https://doi.org/10.1016/j.antiviral.2014.05.005)
Oncology
B Cells in Oncology
Cabrita et al, (2020) Tertiary lymphoid structures improve immunotherapy and survival in melanoma, Nature 577:561-565 (https://doi.org/10.1038/s41586-019-1914-8)
Helmink et al, (2020) B cells and tertiary lymphoid structures promote immunotherapy response, Nature 577:549-555 (https://doi.org/10.1038/s41586-019-1922-8)
Petitprez et al, (2020) B cells are associated with survival and immunotherapy response in sarcoma, Nature 577:556-560 (https://doi.org/10.1038/s41586-019-1906-8)
DeFalco et al, (2018) Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens, Clinical Immunology 187:37-45. (https://doi.org/10.1016/j.clim.2017.10.002)
Bushey et al, (2016) A therapeutic antibody for cancer, derived from single human B cells, Cell Reports (http://doi.org/doi:10.1016/j.celrep.2016.04.038)
IL-38
Takada et al, (2017) Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression, PLOS ONE (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0181598)
